established 90%+ owned businesses with unique high-value patent-protected medical technologies addressing multi-billion dollar markets.

ANGLE's lead product is the Parsortix cell separation device, which can capture very rare circulating tumor cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE has launched a product for the research market and is aiming to secure CE Mark regulatory approval for the clinical market in 2013 with FDA approval in 2014.

ANGLE has a highly efficient investment model. Costs are minimized by the use of third party collaborations and partnerships and by the contribution of its consulting business to overheads. The existing businesses are over six years old. ANGLE's efforts are directed to maximizing shareholder returns from these businesses and there are no plans to set up new companies.

Risk is further offset by the revenue-generating computer graphics company, which has the potential to deliver a near-term capital return to ANGLE.

ANGLE was founded by Andrew Newland in 1994 to bridge a gap between research and the market. ANGLE's business model is to set up, own and operate technology companies to commercialise world-class research.